|
1
|
Wang M, Herbst RS and Boshoff C: Toward
personalized treatment approaches for non-small-cell lung cancer.
Nat Med. 27:1345–1356. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Global Burden of Disease Cancer
Collaboration, . Fitzmaurice C, Allen C, Barber RM, Barregard L,
Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al:
Global, regional, and national cancer incidence, mortality, years
of life lost, years lived with disability, and disability-adjusted
life-years for 32 cancer groups, 1990 to 2015: A systematic
analysis for the global burden of disease study. JAMA Oncol.
3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chaft JE, Rimner A, Weder W, Azzoli CG,
Kris MG and Cascone T: Evolution of systemic therapy for stages
I–III non-metastatic non-small-cell lung cancer. Nat Rev Clin
Oncol. 18:547–557. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li BT, Smit EF, Goto Y, Nakagawa K,
Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E,
et al: Trastuzumab deruxtecan in HER2-mutant non-small-cell lung
cancer. N Engl J Med. 386:241–251. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sezer A, Kilickap S, Gümüş M, Bondarenko
I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Bentsion D, Gladkov
O, et al: Cemiplimab monotherapy for first-line treatment of
advanced non-small-cell lung cancer with PD-L1 of at least 50%: A
multicentre, open-label, global, phase 3, randomised, controlled
trial. Lancet. 397:592–604. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Han J, Liu Y, Yang S, Wu X, Li H and Wang
Q: MEK inhibitors for the treatment of non-small cell lung cancer.
J Hematol Oncol. 14:12021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paz-Ares L, Ciuleanu TE, Cobo M, Schenker
M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E,
Juan-Vidal O, et al: First-line nivolumab plus ipilimumab combined
with two cycles of chemotherapy in patients with non-small-cell
lung cancer (CheckMate 9LA): An international, randomised,
open-label, phase 3 trial. Lancet Oncol. 22:198–211. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hanna NH, Robinson AG, Temin S, Baker S
Jr, Brahmer JR, Ellis PM, Gaspar LE, Haddad RY, Hesketh PJ, Jain D,
et al: Therapy for stage IV non-small-cell lung cancer with driver
alterations: ASCO and OH (CCO) joint guideline update. J Clin
Oncol. 39:1040–1091. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Niu Z, Jin R, Zhang Y and Li H: Signaling
pathways and targeted therapies in lung squamous cell carcinoma:
Mechanisms and clinical trials. Signal Transduct Target Ther.
7:3532022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li L, Li WJ, Zheng XR, Liu QL, Du Q, Lai
YJ and Liu SQ: Eriodictyol ameliorates cognitive dysfunction in
APP/PS1 mice by inhibiting ferroptosis via vitamin D
receptor-mediated Nrf2 activation. Mol Med. 28:112022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen X, Kang R, Kroemer G and Tang D:
Broadening horizons: The role of ferroptosis in cancer. Nat Rev
Clin Oncol. 18:280–296. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Feng L, Zhao K, Sun L, Yin X, Zhang J, Liu
C and Li B: SLC7A11 regulated by NRF2 modulates esophageal squamous
cell carcinoma radiosensitivity by inhibiting ferroptosis. J Transl
Med. 19:3672021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang C, Yu M, Ma J and Zhu Y: Metabolic
classification of bladder cancer based on multi-omics integrated
analysis to predict patient prognosis and treatment response. J
Transl Med. 19:2052021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen X, Kang R, Kroemer G and Tang D:
Targeting ferroptosis in pancreatic cancer: A double-edged sword.
Trends Cancer. 7:891–901. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang R, Xu J, Zhang B, Liu J, Liang C, Hua
J, Meng Q, Yu X and Shi S: Ferroptosis, necroptosis, and pyroptosis
in anticancer immunity. J Hematol Oncol. 13:1102020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Z, Zhao Q, Zuo ZX, Yuan SQ, Yu K,
Zhang Q, Zhang X, Sheng H, Ju HQ, Cheng H, et al: Systematic
analysis of the aberrances and functional implications of
ferroptosis in cancer. iScience. 23:1013022020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang H, Yan M, Li W and Xu L: SIRPα and
PD1 expression on tumor-associated macrophage predict prognosis of
intrahepatic cholangiocarcinoma. J Transl Med. 20:1402022.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao W, Fan W, Wang F, Zhang Y, Wu G, Shi
X, Shi JX, Gao F, Yan M, Guo R, et al: GM-CSF impairs
erythropoiesis by disrupting erythroblastic island formation via
macrophages. J Transl Med. 20:112022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li W, Wang Y, Zhao H, Zhang H, Xu Y, Wang
S, Guo X, Huang Y, Zhang S, Han Y, et al: Identification and
transcriptome analysis of erythroblastic island macrophages. Blood.
134:480–491. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Li W, Schulz VP, Zhao H, Qu X, Qi
Q, Cheng Y, Guo X, Zhang S, Wei X, et al: Impairment of human
terminal erythroid differentiation by histone deacetylase 5
deficiency. Blood. 138:1615–1627. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu L, Yang H, Yan M and Li W: Matrix
metalloproteinase 1 is a poor prognostic biomarker for patients
with hepatocellular carcinoma. Clin Exp Med. 23:2065–2083. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li W, Li T, Sun C, Du Y, Chen L, Du C, Shi
J and Wang W: Identification and prognostic analysis of biomarkers
to predict the progression of pancreatic cancer patients. Mol Med.
28:432022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Malta TM, Sokolov A, Gentles AJ,
Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J,
Omberg L, Gevaert O, et al: Machine learning identifies stemness
features associated with oncogenic dedifferentiation. Cell.
173:338–354.e15. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ralser DJ, Klümper N, Gevensleben H, Zarbl
R, Kaiser C, Landsberg J, Hölzel M, Strieth S, Faridi A, Abramian A
and Dietrich D: Molecular and immune correlates of PDCD1 (PD-1),
PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA methylation in triple
negative breast cancer. J Immunother. 44:319–324. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang M, Du Q, Jin J, Wei Y, Lu Y and Li Q:
LAG3 and its emerging role in cancer immunotherapy. Clin Transl
Med. 11:e3652021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ascierto PA, Puzanov I, Agarwala SS, Blank
C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA,
et al: Perspectives in melanoma: Meeting report from the ‘melanoma
bridge’ (December 5th-7th, 2019, Naples, Italy). J Transl Med.
18:3462020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Z, Zhang Y, Shi C, Zhou X, Xu K, Jiao
D, Sun Z and Han X: A novel immune classification reveals distinct
immune escape mechanism and genomic alterations: Implications for
immunotherapy in hepatocellular carcinoma. J Transl Med. 19:52021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Okła K, Rajtak A, Czerwonka A, Bobiński M,
Wawruszak A, Tarkowski R, Bednarek W, Szumiło J and Kotarski J:
Accumulation of blood-circulating PD-L1-expressing M-MDSCs and
monocytes/macrophages in pretreatment ovarian cancer patients is
associated with soluble PD-L1. J Transl Med. 18:2202020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao B, Xia Y, Yang F, Wang Y, Wang Y,
Wang Y, Dai C, Wang Y and Ma W: Molecular landscape of IDH-mutant
astrocytoma and oligodendroglioma grade 2 indicate tumor purity as
an underlying genomic factor. Mol Med. 28:342022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ravi R, Noonan KA, Pham V, Bedi R,
Zhavoronkov A, Ozerov IV, Makarev E, V Artemov A, Wysocki PT, Mehra
R, et al: Bifunctional immune checkpoint-targeted antibody-ligand
traps that simultaneously disable TGFβ enhance the efficacy of
cancer immunotherapy. Nat Commun. 9:7412018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi
M, Bin J, Liao Y, Rao J and Liao W: Tumor microenvironment
characterization in gastric cancer identifies prognostic and
immunotherapeutically relevant gene signatures. Cancer Immunol Res.
7:737–750. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang J, Sun J, Liu LN, Flies DB, Nie X,
Toki M, Zhang J, Song C, Zarr M, Zhou X, et al: Siglec-15 as an
immune suppressor and potential target for normalization cancer
immunotherapy. Nat Med. 25:656–666. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X,
Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction
and exclusion predict cancer immunotherapy response. Nat Med.
24:1550–1558. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wei J, Huang K, Chen Z, Hu M, Bai Y, Lin S
and Du H: Characterization of glycolysis-associated molecules in
the tumor microenvironment revealed by pan-cancer tissues and lung
cancer single cell data. Cancers (Basel). 12:17882020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wood DE: National comprehensive cancer
network (NCCN) Clinical practice guidelines for lung cancer
screening. Thorac Surg Clin. 25:185–197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Magaki S, Hojat SA, Wei B, So A and Yong
WH: An introduction to the performance of immunohistochemistry.
Methods Mol Biol. 1897:289–298. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Friedmann Angeli JP, Krysko DV and Conrad
M: Ferroptosis at the crossroads of cancer-acquired drug resistance
and immune evasion. Nat Rev Cancer. 19:405–414. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu Q, Qian W, Sun X and Jiang S:
Small-molecule inhibitors, immune checkpoint inhibitors, and more:
FDA-approved novel therapeutic drugs for solid tumors from 1991 to
2021. J Hematol Oncol. 15:1432022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Passaro A, Brahmer J, Antonia S, Mok T and
Peters S: Managing resistance to immune checkpoint inhibitors in
lung cancer: Treatment and novel strategies. J Clin Oncol.
40:598–610. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang D, Tang DG and Rycaj K: Cancer stem
cells: Regulation programs, immunological properties and
immunotherapy. Semin Cancer Biol. 52:94–106. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Clara JA, Monge C, Yang Y and Takebe N:
Targeting signalling pathways and the immune microenvironment of
cancer stem cells-a clinical update. Nat Rev Clin Oncol.
17:204–232. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hänzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cescon DW, She D, Sakashita S, Zhu CQ,
Pintilie M, Shepherd FA and Tsao MS: NRF2 pathway activation and
adjuvant chemotherapy benefit in lung squamous cell carcinoma. Clin
Cancer Res. 21:2499–2505. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ruiz EJ, Diefenbacher ME, Nelson JK,
Sancho R, Pucci F, Chakraborty A, Moreno P, Annibaldi A, Liccardi
G, Encheva V, et al: LUBAC determines chemotherapy resistance in
squamous cell lung cancer. J Exp Med. 216:450–465. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Geeleher P, Cox NJ and Huang RS: Clinical
drug response can be predicted using baseline gene expression
levels and in vitro drug sensitivity in cell lines. Genome Biol.
15:R472014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Goldstraw P, Chansky K, Crowley J,
Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P,
Mitchell A, Bolejack V, et al: The IASLC lung cancer staging
project: Proposals for revision of the TNM stage groupings in the
forthcoming (eighth) edition of the TNM classification for lung
cancer. J Thorac Oncol. 11:39–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Guo L, Ma Y, Ward R, Castranova V, Shi X
and Qian Y: Constructing molecular classifiers for the accurate
prognosis of lung adenocarcinoma. Clin Cancer Res. 12:3344–3354.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Selvaraj G, Kaliamurthi S, Kaushik AC,
Khan A, Wei YK, Cho WC, Gu K and Wei DQ: Identification of target
gene and prognostic evaluation for lung adenocarcinoma using gene
expression meta-analysis, network analysis and neural network
algorithms. J Biomed Inform. 86:120–134. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shi X, Li R, Dong X, Chen AM, Liu X, Lu D,
Feng S, Wang H and Cai K: IRGS: An immune-related gene classifier
for lung adenocarcinoma prognosis. J Transl Med. 18:552020.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cui J, Wen Q, Tan X, Chen Z and Liu G: A
genomic-clinicopathologic nomogram predicts survival for patients
with laryngeal squamous cell carcinoma. Dis Markers.
2019:59805672019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cui J, Wang L, Tan G, Chen W, He G, Huang
H, Chen Z, Yang H, Chen J and Liu G: Development and validation of
nomograms to accurately predict risk of recurrence for patients
with laryngeal squamous cell carcinoma: Cohort study. Int J Surg.
76:163–170. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chen P, Wu Q, Feng J, Yan L, Sun Y, Liu S,
Xiang Y, Zhang M, Pan T, Chen X, et al: Erianin, a novel dibenzyl
compound in Dendrobium extract, inhibits lung cancer cell growth
and migration via calcium/calmodulin-dependent ferroptosis. Signal
Transduct Target Ther. 5:512020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fu X, Liu J, Liu D, Zhou Y, Guo Y, Wang Z,
Yang S, He W, Chen P, Wang X, et al: Glucose-regulated protein 78
modulates cell growth, epithelial-mesenchymal transition, and
oxidative stress in the hyperplastic prostate. Cell Death Dis.
13:782022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xia S, Duan W, Liu W, Zhang X and Wang Q:
GRP78 in lung cancer. J Transl Med. 19:1182021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang W, Green M, Choi JE, Gijón M, Kennedy
PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al:
CD8+ T cells regulate tumour ferroptosis during cancer
immunotherapy. Nature. 569:270–274. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Xu H, Ye D, Ren M, Zhang H and Bi F:
Ferroptosis in the tumor microenvironment: Perspectives for
immunotherapy. Trends Mol Med. 27:856–867. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Torres-Ayuso P, An E, Nyswaner KM, Bensen
RC, Ritt DA, Specht SI, Das S, Andresson T, Cachau RE, Liang RJ, et
al: TNIK Is a therapeutic target in lung squamous cell carcinoma
and regulates FAK activation through merlin. Cancer Discov.
11:1411–1423. 2021. View Article : Google Scholar : PubMed/NCBI
|
